Literature DB >> 23757361

Effect of VX-770 (ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells.

Laura Vachel1, Caroline Norez, Frédéric Becq, Clarisse Vandebrouck.   

Abstract

BACKGROUND: TRPC6 has been proposed to be responsible for the abnormal OAG-dependent Ca(2+) influx in cystic fibrosis (CF) cells and we hypothesized that it interacts with CFTR. Here, we investigated how this functional complex operates in CF and non-CF epithelial cells.
METHODS: Chinese hamster ovary (CHO) cells stably transfected with pNut vector containing wild type CFTR (CHO-WT), F508del-CFTR (CHO-F508del) or G551D-CFTR(CHO-G551D) were used. Calcium channel activity was recorded using Fluo-4 probe and CFTR activity was measured by iodide efflux technique in the presence of CFTR activators (forskolin, genistein) and VX-770, CFTR inhibitor (GPinh5a) and TRPC non-selective modulators (OAG, SKF96365).
RESULTS: CFTR down regulates OAG Ca(2+) response and OAG Ca(2+) influx increases CFTR chloride efflux. Furthermore, we observed potentiation of G551D-CFTR activity when combining VX-770 and OAG.
CONCLUSION: Taking advantage of the functional coupling between OAG-dependent Ca(2+) influx and CFTR, a combination of OAG and VX-770 could be a therapeutic strategy for homozygote patients bearing the G551D-CFTR mutation.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; Calcium signaling; Cystic fibrosis; G551D-CFTR; OAG; TRPC6; VX-770

Mesh:

Substances:

Year:  2013        PMID: 23757361     DOI: 10.1016/j.jcf.2013.05.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

1.  PharmGKB summary: very important pharmacogene information for CFTR.

Authors:  Ellen M McDonagh; John P Clancy; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-03       Impact factor: 2.089

Review 2.  Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

Authors:  Xiaoqing Guan; Yuning Hou; Fei Sun; Zhe Yang; Chunying Li
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

Review 3.  Cystic Fibrosis, CFTR, and Colorectal Cancer.

Authors:  Patricia Scott; Kyle Anderson; Mekhla Singhania; Robert Cormier
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

4.  Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation.

Authors:  Guadalupe Ortiz-Muñoz; Michelle A Yu; Emma Lefrançais; Beñat Mallavia; Colin Valet; Jennifer J Tian; Serena Ranucci; Kristin M Wang; Zhe Liu; Nicholas Kwaan; Diana Dawson; Mary Ellen Kleinhenz; Fadi T Khasawneh; Peter M Haggie; Alan S Verkman; Mark R Looney
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 5.  Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis.

Authors:  Giulio Cabrini; Alessandro Rimessi; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Paolo Pinton; Roberto Gambari
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.